About Aytu Bioscience (NASDAQ:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women's sexual wellbeing and intimacy.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$3.22 million
Price / Sales0.83
Price / CashN/A
Book Value$4.84 per share
Price / Book0.10
Return on Equity-295.55%
Return on Assets-91.13%
Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions
What is Aytu Bioscience's stock symbol?
Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."
When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?
Shares of Aytu Bioscience reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.
How were Aytu Bioscience's earnings last quarter?
Aytu Bioscience Inc (NASDAQ:AYTU) issued its quarterly earnings data on Friday, February, 9th. The company reported ($0.89) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.78) by $0.89. The business had revenue of $1.05 million for the quarter. Aytu Bioscience had a negative return on equity of 295.55% and a negative net margin of 419.34%. View Aytu Bioscience's Earnings History.
Where is Aytu Bioscience's stock going? Where will Aytu Bioscience's stock price be in 2018?
1 Wall Street analysts have issued twelve-month price objectives for Aytu Bioscience's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Aytu Bioscience's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for Aytu Bioscience.
Who are some of Aytu Bioscience's key competitors?
Some companies that are related to Aytu Bioscience include Orexigen Therapeutics (OREX), Dextera Surgical (DXTR), TearLab (TEAR), Rosetta Genomics (ROSG), Lombard Medical Technologies (EVARF), Avinger (AVGR), BG Medicine (BGMD), Tetralogic Pharmaceuticals (TLOG), Affymax (AFFY), Callitas Health In (MPHMF), Imaging Canada Liquidating (IMRSQ), Echo Therapeutics (ECTE) and Patheon (PTHN).
Who are Aytu Bioscience's key executives?
Aytu Bioscience's management team includes the folowing people:
- Joshua R. Disbrow, Chief Executive Officer, Director (Age 42)
- David A. Green CPA, Chief Financial Officer, Treasurer, Secretary (Age 55)
- Jarrett T. Disbrow, Chief Operating Officer
- Michael Macaluso, Director (Age 66)
- Gary V. Cantrell, Independent Director
- Carl C Dockery, Independent Director (Age 53)
- John Donofrio Jr., Independent Director
Has Aytu Bioscience been receiving favorable news coverage?
News articles about AYTU stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aytu Bioscience earned a news sentiment score of 0.00 on Accern's scale. They also assigned media coverage about the company an impact score of 44.63 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Aytu Bioscience's major shareholders?
Aytu Bioscience's stock is owned by many different of institutional and retail investors. Top institutional investors include Armistice Capital LLC (7.38%). Company insiders that own Aytu Bioscience stock include David A Green and Jarrett Disbrow. View Institutional Ownership Trends for Aytu Bioscience.
Which major investors are buying Aytu Bioscience stock?
AYTU stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC. Company insiders that have bought Aytu Bioscience stock in the last two years include David A Green and Jarrett Disbrow. View Insider Buying and Selling for Aytu Bioscience.
How do I buy shares of Aytu Bioscience?
Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aytu Bioscience's stock price today?
One share of AYTU stock can currently be purchased for approximately $0.48.
How big of a company is Aytu Bioscience?
Aytu Bioscience has a market capitalization of $2.40 million and generates $3.22 million in revenue each year. The company earns $-22,500,000.00 in net income (profit) each year or ($16.41) on an earnings per share basis. Aytu Bioscience employs 63 workers across the globe.
How can I contact Aytu Bioscience?
Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]
MarketBeat Community Rating for Aytu Bioscience (AYTU)MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aytu Bioscience (NASDAQ:AYTU) Earnings History and Estimates Chart
Aytu Bioscience (NASDAQ AYTU) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/9/2018||Q2 2018||($1.78)||($0.89)||$1.05 million||View||N/A|
|11/9/2017||Q1 2018||($7.60)||($1.76)||$1.08 million||View||N/A|
|8/31/2017||Q4 2017||($12.00)||($4.16)||$0.84 million||View||N/A|
|5/11/2017||Q3 2017||($0.28)||($0.48)||$1.08 million||$0.89 million||View||N/A|
|2/9/2017||12/31/2016||($0.52)||($0.55)||$1.11 million||$0.79 million||View||N/A|
|11/7/2016||Q1 2017||($0.84)||($1.17)||$1.20 million||$0.70 million||View||N/A|
|9/1/2016||Q4 2016||($15.60)||($45.40)||$0.70 million||$0.94 million||View||N/A|
|5/11/2016||Q3 2016||($93.64)||$0.67 million||View||N/A|
Aytu Bioscience (NASDAQ:AYTU) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Aytu Bioscience (NASDAQ:AYTU)
No dividend announcements for this company have been tracked by MarketBeat.com
Aytu Bioscience (NASDAQ AYTU) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 7.27%
Aytu Bioscience (NASDAQ AYTU) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/6/2018||David A Green||CFO||Buy||66,600||$0.45||$29,970.00|| |
|3/6/2018||Jarrett Disbrow||COO||Buy||226,105||$0.45||$101,747.25|| |
|1/20/2016||Joshua R Disbrow||CEO||Buy||153,846||$0.65||$99,999.90||153,846|| |
Aytu Bioscience (NASDAQ AYTU) News Headlines
|Aytu BioScience Presents New Research Findings for Natesto(R) at the Endocrine Society's 100th Annual Meeting|
finance.yahoo.com - March 20 at 9:58 AM
|Has Aytu BioScience Inc (NASDAQ:AYTU) Improved Earnings Growth In Recent Times?|
finance.yahoo.com - March 9 at 10:40 AM
|BRIEF-Bigger Capital Fund Reports 7.4 Pct Passive Stake In Aytu Bioscience As Of March 2|
www.reuters.com - March 8 at 4:58 PM
|Form 4 AYTU BIOSCIENCE, INC For: Mar 06 Filed by: Disbrow Jarrett|
www.streetinsider.com - March 8 at 10:10 AM
|Aytu Bioscience Inc (AYTU) CFO David A. Green Acquires 66,600 Shares|
www.americanbankingnews.com - March 7 at 7:46 PM
|Insider Buying: Aytu Bioscience Inc (AYTU) COO Buys 226,105 Shares of Stock|
www.americanbankingnews.com - March 7 at 7:15 PM
|Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico|
finance.yahoo.com - March 7 at 9:55 AM
|Aytu BioScience Announces Closing of $12,000,000 Public Offering|
finance.yahoo.com - March 6 at 4:35 PM
|Aytu Bioscience (AYTU) Announces Quarterly Earnings Results|
www.americanbankingnews.com - February 9 at 11:02 AM
|Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET|
finance.yahoo.com - February 8 at 4:35 PM
|Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update|
finance.yahoo.com - February 1 at 9:02 AM
|Aytu Bioscience (AYTU) Scheduled to Post Earnings on Wednesday|
www.americanbankingnews.com - January 31 at 2:10 AM
|Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?|
finance.yahoo.com - January 2 at 10:29 AM
|Aytu BioScience, Inc. to Present at the 10th Annual LD Micro Main Event|
finance.yahoo.com - November 29 at 10:48 AM
|Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.|
finance.yahoo.com - November 28 at 11:15 AM
|Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017|
finance.yahoo.com - November 28 at 11:15 AM
|BRIEF-Aytu Bioscience files for mixed shelf of upto $100 mln|
www.reuters.com - November 22 at 10:00 PM
|AYTU BIOSCIENCE, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - November 16 at 8:55 PM
|Q1 2017 Aytu BioScience Inc Earnings Release - Time Not Supplied|
biz.yahoo.com - November 7 at 1:40 PM
|AYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen|
biz.yahoo.com - November 2 at 10:18 PM
|Aytu BioScience Further Demonstrates Clinical Utility for MiOXSYS™ System as an Aid in the Diagnosis of Male Infertility|
www.prnewswire.com - November 1 at 9:11 PM
|Aytu BioScience to Present at Two Upcoming Investor Conferences|
www.prnewswire.com - September 14 at 3:43 PM
|Q4 2016 Aytu BioScience Inc Earnings Release - Time Not Supplied|
biz.yahoo.com - September 1 at 12:09 PM
|AYTU BIOSCIENCE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi|
biz.yahoo.com - September 1 at 12:09 PM
|Acerus Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q2 2016 Results - Earnings Call Transcript|
seekingalpha.com - August 9 at 4:48 PM
|AYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu|
biz.yahoo.com - August 2 at 8:29 AM
|Testosterone replacement treatment is opportunity for Colorado company|
www.bizjournals.com - July 8 at 8:52 PM
Aytu Bioscience (NASDAQ:AYTU) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Aytu Bioscience (NASDAQ AYTU) Stock Chart for Friday, March, 23, 2018